Login / Signup

Enhanced disulphide bond stability contributes to the once-weekly profile of insulin icodec.

Frantisek HubálekChristian N CramerHans HellebergEva JohanssonErica NishimuraGerd SchluckebierDorte Bjerre SteensgaardJeppe SturisThomas B Kjeldsen
Published in: Nature communications (2024)
Insulin icodec is a once-weekly insulin analogue that has a long half-life of approximately 7 days, making it suitable for once weekly dosing. The Insulin icodec molecule was developed based on the hypothesis that lowering insulin receptor affinity and introducing a strong albumin-binding moiety would result in a long insulin half-life, provided that non-receptor-mediated clearance is diminished. Here, we report an insulin clearance mechanism, resulting in the splitting of insulin molecules into its A-chain and B-chain by a thiol-disulphide exchange reaction. Even though the substitutions in insulin icodec significantly stabilise insulin against such degradation, some free B-chain is observed in plasma samples from minipigs and people with type 2 diabetes. In summary, we identify thiol-disulphide exchange reactions to be an important insulin clearance mechanism and find that stabilising insulin icodec towards this reaction significantly contributes to its long pharmacokinetic/pharmacodynamic profile.
Keyphrases
  • type diabetes
  • glycemic control
  • mass spectrometry
  • skeletal muscle
  • transcription factor
  • binding protein
  • dna binding